STOCK TITAN

Nanostring Technologies Inc - NSTG STOCK NEWS

Welcome to our dedicated news page for Nanostring Technologies (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on Nanostring Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nanostring Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nanostring Technologies's position in the market.

Rhea-AI Summary
NanoString Technologies, Inc. reported Q3 revenue of $48.1 million, a 63% YoY growth and above the upper end of Q3 guidance range. The company completed an exchange transaction with convertible note holders representing 94% of outstanding principal. They exchanged approximately $216 million of Convertible Notes for new Senior Secured Notes and common stock warrants. NanoString aims to achieve profitability in 2025 and has updated its financial outlook for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
earnings
-
Rhea-AI Summary
NanoString Technologies announces researchers sharing first insights utilizing the GeoMx Immuno-oncology Proteome Atlas at the 38th annual meeting of the Society for Immunotherapy of Cancer. The GeoMx IPA is the industry's most comprehensive spatial proteomics panel, allowing spatial profiling of over 570 relevant targets. The assay offers more than five times the content of any competing panel and has applications in biomarker discovery, drug target investigation, therapeutic response, patient stratification, and drug mechanism determination.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
Rhea-AI Summary
UPC denies second preliminary injunction request against NanoString Technologies, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.5%
Tags
none
Rhea-AI Summary
UPC denies second preliminary injunction request against NanoString Technologies, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
none
-
Rhea-AI Summary
NanoString Technologies reports Q3 revenue of over $48 million, exceeding guidance and consensus estimates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.5%
Tags
none
-
Rhea-AI Summary
A*STAR's Genome Institute of Singapore, NanoString Technologies, and Next Level Genomics announce the establishment of a joint lab in Singapore focusing on spatial biology to identify biomarkers for disease progression and treatment response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
none
Rhea-AI Summary
European Unified Patent Court issues preliminary injunction against NanoString for infringing EP 782 patent, preventing sales in 17 countries of the UPC. 10x Genomics intends to seek more than $30 million in damages for sales prior to trial in the US case. Trial for second US suit against NanoString scheduled for September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.94%
Tags
none
-
Rhea-AI Summary
European Unified Patent Court issues preliminary injunction against NanoString for infringing EP 782 patent, preventing sales in 17 countries of the UPC. 10x Genomics intends to seek more than $30 million in damages for sales prior to trial in the US case. Trial for second US suit against NanoString scheduled for September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary
NanoString to appeal preliminary injunction in patent dispute with 10x Genomics and Harvard
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.94%
Tags
none
Rhea-AI Summary
NanoString Technologies, Inc. will host its fifth annual Spatial Genomics Summit, showcasing advances in spatial biology and introducing new products. Highlights include the introduction of new spatial biology products and the application of NanoString's platforms in various research areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
Nanostring Technologies Inc

Nasdaq:NSTG

NSTG Rankings

NSTG Stock Data

5.07M
39.41M
3.17%
106.45%
12.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Seattle

About NSTG

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali